Deadline Alert: Zoetis Inc. (ZTS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming July 27, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Zoetis Inc. (“Zoetis” or the “Company”) (NYSE: ZTS ) securities between January 14, 2025 and May 6, 2026 , inclusive (the “Class Period”).

What Happened? On August 5, 2025, Zoetis released its second quarter 2025 financial results, reporting weakened demand trends within its Companion Animal portfolio. On this news, Zoetis’ stock price fell $5.69, or 3.8%, to close at $146.12 per share on August 5, 2025, thereby injuring investors.

Then, on November 4, 2025, Zoetis released its third quarter 2025 financial results, revealing slowed growth across its key Companion Animal franchises and disclosing continued weakness in sales of its canine pain treatment, Librela, and increased competitive pressure in dermatology and parasiticides. The Company also lowered its full year sales outlook. On this news, Zoetis’ stock price fell $19.89, or 13.8%, to close at $124.46 per share on November 4, 2025.

Then, on May 7, 2026, Zoetis released its first quarter 2026 financial results, reporting slowing overall revenue growth, declining Companion Animal sales performance, and worsening results across its key dermatology and parasiticides franchises, stating that “competition intensified across key pet care categories, including dermatology and parasi...